Loading…

The Federal Trade Commission has moved to block Edwards Lifesciences' purchase of JenaValve Technology and its Trilogy transcatheter heart valve system for treating aortic regurgitation. Edwards plans to continue pursuing the deal, with a final determination expected by the end of March 2026.
“The Federal Trade Commission has moved to block Edwards Lifesciences’ purchase of JenaValve Technology and its transcatheter heart valve implant for treating aortic regurgitation.”fiercebiotech.com
Summarized from public sources; check the original articles before acting on it.